#MetaplasticBreastCancer Spindle cell/Sarcomatous histologic type N=36 is associated with reduced 3-/5-yr Recurrence-free survival & Overall survival vs other histologic types N=70 In this cohort, MpBC N=106 vs non-Mp TNBC N=106 have similar survival Discussion contains an important summary of previous studies on MpBC prognosis. @CBCjournal 2025 clinical-breast-cancer.com/a…

Systematic review of nonpharmacological interventions for postmastectomy pain syndrome (PMPS). 🔹 Fat grafting & lymph node transplantation → ⬆️QoL & ⬇️pain 🔹 Pulsed radiofrequency 🔹 TENS & dry needling → most effective PT approaches #bcsm sciencedirect.com/science/ar…

Real-World Analysis of BC pts Qualifying for Adjuvant CDK4/6i (n=3,840) 🔹 17.5% met abemaciclib eligibility 🔹 41.3% met ribociclib eligibility 🔹 Eligible pts had lower stage/nodal burden vs phase III trials #bcsm clinical-breast-cancer.com/a…

In HER2 positive #DCIS treated with BCS RT, a 7-gene biosignature (DCISionRT) with Residual Risk subtype (RRt) identified patients at significantly higher 10-yr in-breast recurrence risk (16.2% vs 1.6%). #bcsm clinical-breast-cancer.com/a…

Progesterone receptor (PR) expression in #BreastCancer is more than a biomarker. 🔹 Analysis of 2,223 pts (IPO-Porto) 🔹 PR status linked to BMI, histology, grade, stage, ER & HER2 🔹 PR– tumors associated with advanced stage & worse OS #bcsm sciencedirect.com/science/ar…

Is breast-conserving therapy (BCT) safe for multifocal/multicentric breast cancer (MF/MCBC)? 🔹Meta-analysis (28,589 pts) 🔹 MF/MCBC had higher LR vs unifocal disease 🔹 LR rates comparable btw BCT & mastectomy 🔹 DFS & OS outcomes favorable #bcsm clinical-breast-cancer.com/a…

Solution 🌳of Sustainability for Breast Cancer Care 👇 Grateful to ✍️ co- authors for their insights

Climate change is the greatest threat to human health—and it directly impacts BC care. This review maps intersections between breast cancer care & planetary health and proposes a solution tree for sustainable, low-carbon practice. #bcsm @Seamusoreilly18 sciencedirect.com/science/ar…

Black women face higher breast cancer mortality despite similar incidence to White women. 🧬 Universal genetic counseling/testing could aid earlier risk identification ⚡ Higher TNBC rates & earlier onset already meet NCCN criteria #bcsm @sofiamerajver clinical-breast-cancer.com/a…

💡 In HER2 breast cancer patients who achieve pCR after neoadjuvant chemo trastuzumab/pertuzumab (TP), adjuvant therapy choice may not impact outcomes. 👉 3-yr RFS: 94.2% (TP) vs 95.6% (T) 👉 No differences in brain mets or survival #bcsm #CBCjournal clinical-breast-cancer.com/a…

A new article was published in Clinical Breast Cancer by the cancer center’s Tarah Ballinger, MD, and colleagues. Learn more: ow.ly/pgYz50WGiqk. #ResearchCuresCancer #NCIcomprehensive @CBCjournal

New meta-analysis: Tranexamic acid (TXA) significantly reduces postoperative hematoma after breast surgery. 🔹 Both topical & IV TXA cut hematoma risk 🔹 Less drain output & earlier drain removal 🔹 No increase in infection or thromboembolic events #bcsm sciencedirect.com/science/ar…

PreciseDx Breast is a digital risk assessment test that predicts early BC recurrence within 6-years of diagnosis. Read more👇 #bcsm @IcahnMountSinai clinical-breast-cancer.com/a…

Radiation omission in pts w/ early BC is a dynamically changing paradigm. Individualizing treatment is paramount and understanding an individual pt's goals of treatments and values is key. Read more 👇 #bcsm @RoswellPark @si_fkf @MFarrugiaXRT @CShahMD clinical-breast-cancer.com/a…

A study evaluating forequarter amputation (FA) in BC (locally advanced/recurrent tumor, Stewart & Treves syndrome, radiation-induced sarcoma) showed that FA has few complications & attenuates symptoms in pts tx with both curative & palliative intent. sciencedirect.com/science/ar…

🔔Hot off the press! Optimizing Postneoadjuvant Treatment of Residual #BreastCancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy 🔓Free access until 03/21: sciencedirect.com/science/ar… ✍️@CBCjournal @darioT_ @JinQingchun @hoperugo @YAbdouMD @CARLAISADORA @NabihahTayob @stolaney1 @DrHBurstein @elmayermd

A Clinical Review on Antibody-Drug Conjugates in TNBC, summarizing Current Data and Future Developments. @kilicmerwe @WinshipAtEmory pubmed.ncbi.nlm.nih.gov/3834…

Just published in the February 2025 issue of Clinical Breast Cancer @CBCjournal Congratulations to Professor Yihong Wang and colleagues @BrownMedicine @BrownUCancer @BrownPathology     In our study of 224 node-positive breast cancer patients treated with neoadjuvant chemotherapy, we found that axillary and locoregional recurrences were rare (3.4%) in a selected group of yN0 patients who underwent SLNB and/or ALND. Additionally, SLNB with fewer than two positive nodes rarely resulted in a significantly different yield of positive non-SLNs or impacted short-term oncologic outcomes compared to ALND. These findings suggest that de-escalation of axillary surgery to SLNB alone may be a safe option in this patient population. Full article available at the following link sciencedirect.com/science/ar…

A Clinical Review of the Role of Immunotherapy in TNBC, with an Overview of Data from Seminal Trials for both Early and Advanced TNBC. #bcsm @RitaNandaMD @UChicagoMed pubmed.ncbi.nlm.nih.gov/3858…

NH Black women have ⬆️ risk of TNBC yet, they are less likely to undergo genetic counseling / testing and less likely to receive guideline-directed screening and risk-reduction compared to NH White women. #bcsm #disparities @dsmithgraz @WinshipAtEmory pubmed.ncbi.nlm.nih.gov/3947…